Publications by authors named "Pierfranco Conte"

Claim this Profile
T
The Impact of Concordance between Liquid and Tissue Biopsy for Actionable Mutations: Insights from the ROME Trial.
Andrea Botticelli, Chiara Cremolini, Simone Scagnoli, Mauro Biffoni, Sara Lonardi, Pierfranco Conte

Clin Cancer Res· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.
Alberto Bongiovanni, Pierfranco Conte, Vincenza Conteduca, Matteo Landriscina, Giuseppe Di Lorenzo

Curr Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare costs of cutaneous melanoma according to comorbidity patterns: a population-based study from the Regional Cancer Registry of the Veneto Region.
Alessandra Buja, Fortunato Cassalia, Massimo Rugge, Chiara Trevisiol, Manuel Zorzi, Pierfranco Conte

Front Public Health· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of comorbidities on survival in melanoma patients.
Alessandra Buja, Fortunato Cassalia, Massimo Rugge, Chiara Trevisiol, Manuel Zorzi, Pierfranco Conte

BMC Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.
Egbert F Smit, Simon M Collin, Manoj Prahladan, Flavia Lujan, Emma Drane, Pierfranco Conte

Future Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.
Paolo Marchetti, Giuseppe Curigliano, Mauro Biffoni, Sara Lonardi, Simone Scagnoli, Pierfranco Conte

Nat Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigating the Trajectories of Association Between Biomarkers and Cancer-Related Cognitive Impairment in Patients with Breast Cancer: A Systematic Review.
Angela Boschetti, Laura Danesin, Elisa Bevilacqua, Riccardo Giada, Massimo Gion, Pierfranco Conte

Cancers (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis.
Guillermo Villacampa, Tomás Pascual, Paolo Tarantino, Javier Cortés, José Perez-García, Pierfranco Conte

Lancet Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Healthcare Costs by Comorbidity Patterns in Lung Cancer Patients.
Alessandra Buja, Massimo Rugge, Marcello Di Pumpo, Manuel Zorzi, Federico Rea, Pierfranco Conte

Cancers (Basel)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for 30-day unplanned readmissions after surgical procedures in the elderly population.
Gino Sartor, Marco Fusco, Marzio Milana, Leonardo Rigon, Giorgio Arcara, Pierfranco Conte

Patient Saf Surg· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data.
Helena M Earl, Louise Hiller, Janet A Dunn, Mubarak Patel, PierFranco Conte

BMJ Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patterns of Comorbidities in Lung Cancer Patients and Survival.
Alessandra Buja, Marcello Di Pumpo, Massimo Rugge, Manuel Zorzi, Federico Rea, Pierfranco Conte

Cancers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer: 10-Year Analysis of the ShortHER Randomized Clinical Trial.
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Alessio Schirone, Luigi Cavanna, Pierfranco Conte

JAMA Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NON-SMALL-CELL LUNG CANCER: Real-World Population-Based Cohorts' Study.
Alessandra Buja, Massimo Rugge, Alberto Bortolami, Manuel Zorzi, Federico Rea, Pierfranco Conte

Cancers (Basel)· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tailoring neoadjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
Hesham Elghazaly, Hamdy A Azim, Hope S Rugo, David Cameron, Sandra M Swain, Pierfranco Conte

Cancer· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to M. Kusumoto et al.
Pierfranco Conte, Valentina Guarneri, Roberto D'Amico

J Clin Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Positioning of tucatinib in the new clinical scenario of HER2-positive metastatic breast cancer: An Italian and Spanish consensus paper".
Pierfranco Conte, Eva Ciruelos, Giuseppe Curigliano, Michelino De Laurentiis, Lucia Del Mastro

Breast· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cognitive impairment following breast cancer treatments: an umbrella review.
Giulia Oliva, Andreina Giustiniani, Laura Danesin, Francesca Burgio, Giorgio Arcara, Pierfranco Conte

Oncologist· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer.
Maria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati

J Natl Cancer Inst· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread.
Carmen Criscitiello, Chiara Corti, Michelino De Laurentiis, Giampaolo Bianchini, Barbara Pistilli, Pierfranco Conte

Cancer Treat Rev· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.
PierFranco Conte, Giancarlo Bisagni, Federico Piacentini, Samanta Sarti, Santino Minichillo

J Clin Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining technology-assisted rehabilitation for older adults' functional mobility: a network meta-analysis on efficacy and acceptability.
Błażej Cieślik, Justyna Mazurek, Adam Wrzeciono, Lorenza Maistrello, Joanna Szczepańska-Gieracha, Pierfranco Conte

NPJ Digit Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.
Pierre Squifflet, Everardo D Saad, Sibylle Loibl, Marion T van Mackelenbergh, Michael Untch, Pierfranco Conte

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch, Marc Buyse, Charles E Geyer, Pierfranco Conte

J Clin Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial.
Maria Vittoria Dieci, Giancarlo Bisagni, Stefania Bartolini, Antonio Frassoldati, Roberto Vicini, Pierfranco Conte

NPJ Breast Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis